These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36516040)

  • 21. Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
    Saeki I; Yamasaki T; Maeda M; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
    PLoS One; 2019; 14(6):e0218136. PubMed ID: 31194789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.
    Chen XL; Yu HC; Fan QG; Yuan Q; Jiang WK; Rui SZ; Zhou WC
    Oncol Lett; 2022 Oct; 24(4):366. PubMed ID: 36238837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review.
    Zhang W; Ouyang D; Huang Z; Che X
    Front Oncol; 2023; 13():1085166. PubMed ID: 36776344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
    Oh MJ; Lee HJ; Lee SH
    Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis.
    Si T; Shao Q; Jassem W; Ma Y; Heaton N
    Int J Surg; 2024 Aug; ():. PubMed ID: 39093862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
    Kang MK; Park JG; Lee HJ
    Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis.
    Cao YZ; Zheng GL; Zhang TQ; Shao HY; Pan JY; Huang ZL; Zuo MX
    World J Gastroenterol; 2024 Jan; 30(4):318-331. PubMed ID: 38313229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
    Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K
    BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis.
    Li Y; Liu W; Chen J; Chen Y; Guo J; Pang H; Zhang W; An C; Li C
    Cancer Med; 2024 Jan; 13(1):e6836. PubMed ID: 38196277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM
    J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Kong SY; Song JJ; Jin YQ; Deng MJ; Yan JX
    Acta Clin Belg; 2023 Apr; 78(2):171-179. PubMed ID: 35587164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
    World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Li S; Xu J; Zhang H; Hong J; Si Y; Yang T; He Y; Ng DM; Zheng D
    Chemotherapy; 2021; 66(4):124-133. PubMed ID: 34515082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Ouyang G; Pan G; Xu H; Wu Y; Liu Z; Lu W; Yi B; Chen X
    J Clin Gastroenterol; 2020 Sep; 54(8):675-681. PubMed ID: 32569032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
    Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma.
    Liang RB; Zhao Y; He MK; Wen DS; Bu XY; Huang YX; Lai ZC; Xu YJ; Kan A; Wei W; Zhang YJ; Chen MS; Guo RP; Li QJ; Shi M
    Front Oncol; 2021; 11():619461. PubMed ID: 34055599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
    Ahn YE; Suh SJ; Yim HJ; Seo YS; Yoon EL; Kim TH; Lee YS; Yim SY; Kim HR; Kang SH; Jung YK; Kim JH; Yeon JE; Um SH; Byun KS
    Gut Liver; 2021 Mar; 15(2):284-294. PubMed ID: 32307975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.